These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26231708)

  • 1. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
    Arumugasamy K; Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-Based De Novo Design of Cyclin-Dependent Kinase 2 Inhibitors.
    Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():47-58. PubMed ID: 26231707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
    Sims PA; Wong CF; McCammon JA
    J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting structural principles to design cyclin-dependent kinase inhibitors.
    Noble M; Barrett P; Endicott J; Johnson L; McDonnell J; Robertson G; Zawaira A
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):58-64. PubMed ID: 16361058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
    Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
    ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing inhibitors of cyclin-dependent kinases.
    Hardcastle IR; Golding BT; Griffin RJ
    Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
    Brown NR; Noble ME; Endicott JA; Johnson LN
    Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
    Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
    J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Structural Descriptors on the Design of Cyclin Dependent Kinase Inhibitors Using Similarity-based Molecular Evolution.
    Kawai K; Karuo Y; Tarui A; Sato K; Omote M
    Mol Inform; 2020 May; 39(5):e1900126. PubMed ID: 31943821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
    Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
    Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
    Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
    Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
    Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
    J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.